TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00040365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine trihydrate
Description: 1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
Study: NCT01134276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biliary drainage
Description: biliary drainage via PTBD or ERBD/ENBD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biliary drainage
Description: biliary drainage via PTBD or ERBD/ENBD
Study: NCT01691690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Morphine 0.1 mg/kg given prior to intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
Study: NCT02880397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia mangostana
Description: The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
Study: NCT02429817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single photon emission computed tomography
Description: Imaging technique to investigate lung aerosol distribution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single photon emission computed tomography
Description: Imaging technique to investigate lung aerosol distribution
Study: NCT02880397

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
Study: NCT02655445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-craniotomy
Description: chronic subdural hematoma evacuation through minicraniotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Twist Drill Craniostomy
Description: chronic subdural hematoma evacuation through twist drill craniostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burr Hole Craniostomy
Description: chronic subdural hematoma evacuation through burr holes
Study: NCT05476198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachial plexus block
Description: The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
Study: NCT05476198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
Study: NCT01167582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Description: Liberal versus restrictive transfusion
Study: NCT03581071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-143
Study: NCT03347136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study: NCT01691690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
Study: NCT02429817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: FEV1, FVC assessment
Study: NCT04823767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single anastomosis sleeve jejunal bypass with hiatal repair
Description: Single anastomosis sleeve jejunal bypass with hiatal repair
Study: NCT03347136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Study: NCT03916523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation
Description: Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~1. On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~2. On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~3. On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~4. On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: Preterm infants will receive CPAP for respiratory support.
Study: NCT02695654

Intervention type: DRUG
Intervention: Levobupivacaine
Description: 14 ml of 0,25 % Levobupivacaine

Intervention type: DRUG
Intervention: Clonidine
Description: Clonidine 100 mcg
Study: NCT03005392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention).
Study: NCT03386331

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: diet and exercise
Description: Diet and lifestyle intervention
Study: NCT00061919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, etoposide & thalidomide
Description: Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
Study: NCT00764283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm dressing
Description: Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epi-Fix dressing
Description: Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
Study: NCT03421184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urine sample
Description: 10 ml
Study: NCT00061919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin, etoposide & placebo
Description: Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
Study: NCT03916523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Preterm infants in this group will receive mechanical ventilation for respiratory support
Study: NCT03421184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine sample
Description: 10 ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urine sample
Description: 10 ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food questionnaire
Description: dietary habit enquiry and a 48h dietary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food questionnaire
Description: dietary habit enquiry and a 48h dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food questionnaire
Description: dietary habit enquiry and a 48h dietary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hair
Description: lock of hair

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hair
Description: lock of hair
Study: NCT03398746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LOOP Technique
Description: Placement of subcutaneous loop drain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard incision and drainage
Description: Incise and drain with placement of packing
Study: NCT04262401

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard health coaching
Description: 12 weekly sessions of standard health coaching followed by 4 monthly sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit-focused health coaching
Description: 12 weekly sessions of standard health coaching followed by 4 monthly sessions
Study: NCT02168803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study: NCT01290445

Intervention type: DRUG
Intervention: varenicline
Description: This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.

Intervention type: BEHAVIORAL
Intervention: cigarette smoke from maternal smoking
Description: This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
Study: NCT00764283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lockit-Plus
Description: Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
Study: NCT01290445

Intervention type: OTHER
Intervention: Non-Exposure
Description: This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
Study: NCT00674518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One on one counseling
Description: Motivational Interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group/team - based health education
Description: peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE physician counseling
Description: PACE format for physician exercise and nutrition counseling annually.
Study: NCT03421184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hair
Description: lock of hair
Study: NCT01690754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Reminders
Description: Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
Study: NCT03564886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperosmolar Saline
Description: The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Lactate Ringer's (LR, 273mOsm/L)
Study: NCT02445599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Orally 100 mg Diclofenac, administered 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 5 mg Dormicum intramuscularly, administered 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 5 mg Dormicum intramuscularly, administered 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: 0.5 mg Atropine intramuscularly, administered 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: 0.5 mg Atropine intramuscularly, administered 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bucain + fentanyl
Description: Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bucain + fentanyl
Description: Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
Study: NCT01691690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
Study: NCT00253110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Study: NCT01708798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03070678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT03319797

Intervention type: DRUG
Group type: OTHER
Intervention: NOVOCART® Inject plus
Description: Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
Study: NCT02445599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: 1st choice for rescue analgetic 10-20 mg intravenously
Study: NCT01071460

Intervention type: DEVICE
Group type: OTHER
Intervention: FlexStent Femoropopliteal Self-Expanding Stent System
Description: Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~* Contralateral retrograde common femoral cross-over access or antegrade access~* Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~* Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~* Deployment of an appropriately sized FlexStent® to cover target lesion~* Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~* Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications
Study: NCT03023800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Macular buckling
Description: Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
Study: NCT02445599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: 1st choice for rescue analgetic 10-20 mg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 2nd choice for rescue analgetic 250ml intravenously
Study: NCT03324321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypocapnia via Hyperventilation Protocol
Description: 90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
Study: NCT02445599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 2nd choice for rescue analgetic 250ml intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole-sodium
Description: Additional rescue analgetic 2g intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole-sodium
Description: Additional rescue analgetic 2g intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Additional rescue analgetic 100mg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Additional rescue analgetic 100mg intravenously
Study: NCT00607971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renzapride
Description: All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
Study: NCT02692170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-001
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-001
Description: Investigational Product
Study: NCT01093131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral hydration
Description: Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral hydration
Description: Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral sodium bicarbonate
Description: Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Hydration
Description: Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Hydration
Description: Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sodium bicarbonate
Description: Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
Study: NCT03913351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
Study: NCT03946969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Paclitaxel + Cisplatin + S-1
Description: Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
Study: NCT04279743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 phospholipids
Description: The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele.
Study: NCT02546362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly
Study: NCT03023800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia